Details Of Revive Therapeutics' Update On Bucillamine Phase 3 Trial For COVID Treatment Revive Therapeutics (OTC: RVVTF) has provided an update on Phase 3 of its Buc Benzinga · Apr 28, 2022
FDA proposes ban on menthol cigarettes, flavored cigars WASHINGTON — The Food and Drug Administration on Thursday proposed a long-awaited ban on menthol cigarettes and flavored cigars, targeting products used by more than a third of smokers. Tribune News Service · Apr 28, 2022
FDA proposes ban on menthol cigarettes FDA commissioner Robert Califf said these rules "are appropriate for the protection of public health." Axios · Apr 28, 2022
Baxter's FDA Review For Novum IQ Large Volume Pump Put On Hold, Lowers FY22 EPS Outlook Baxter International Inc (NYSE:BAX) has posted Q1 revenue of $3.71 billion, beating the consensus of $3.68 billion, up 26% on a reported basis, 29% on a constant currency basis, and 3% on an operational basis. Adjusted EPS of $0.93 increased 22%, ahead of the consensus of $0.80. Baxter's newly acquired Hillrom businesses… Benzinga · Apr 28, 2022
Moderna seeks FDA approval of Covid vaccine for children aged six months to five years old The request arrives one month after the drug company said its two-dose jabs provided immune protection in youngest children The Independent UK · Apr 28, 2022
FDA to issue plan banning menthol in cigarettes, cigars The U.S. government is set to release its long-awaited plan to ban menthol cigarettes and flavored cigars The Independent UK · Apr 28, 2022
Could Biden Extinguish Tobacco Stocks With This Regulation? The U.S. government could be speeding up a plan to ban menthol cigarettes, according to a new report. Here’s the new timeline and two stocks that could be affected. Benzinga · Apr 28, 2022
TransMedics Receives FDA Premarket Approval for OCS™ DCD Heart Indication TransMedics Group, Inc. (NASDAQ: TMDX) received premarket approval (PMA) from U.S. Food and Drug Administration (FDA) for its OCS™ Heart System in favour of use with organs from donors after circulatory death (DCD). Benzinga · Apr 28, 2022
Moderna applies for US clearance of COVID shot for young kids Moderna Inc. applied for emergency use authorization for its COVID-19 vaccine in children from six months to under 6 years old after a successful trial showed two doses generate high levels of antibodies to the virus. Tribune News Service · Apr 28, 2022
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Apr 28, 2022
Timber Pharmaceutical Gets FDA Fast Track designation for TMB-001 in Severe Subtypes of Congenital Ichthyosis Timber Pharmaceuticals, Inc. (NYSE: TMBR) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TMB-001 for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI). Benzinga · Apr 28, 2022
FDA proposes ban on menthol cigarettes, flavored cigars - Roll Call The FDA Thursday proposed a ban on menthol cigarettes and all flavored cigars, a move that could take effect in about a year. Roll Call · Apr 28, 2022
Moderna seeks to be 1st with COVID shots for littlest kids Moderna is asking U.S. regulators to open its COVID-19 vaccine to the nation's youngest children The Independent UK · Apr 28, 2022
Moderna seeks emergency authorization for COVID-19 vaccine in young children Moderna said last month its vaccine for kids generated a strong immune response. Axios · Apr 28, 2022
Benzinga · Apr 28, 2022 Y-MAbs Therapeutics' CEO Exits, Expects FY22 Danyelza Sales of Up To $50M Y-mAbs Therapeutics Inc's (NASDAQ:YMAB) CEO and Board Member, Claus Moller, has stepped down from his position effective immediately. Thomas Gad, the Company's Founder, Chairman & President, has assumed the interim CEO and Board Member role. In addition, Mr. Gad has stepped down as Chairman, and Jim Healy, current Board Member and Chair of…
Roll Call · Apr 28, 2022 Moderna asks FDA to authorize COVID-19 vaccine for kids under 6 - Roll Call Moderna said Thursday that it asked the FDA for emergency use authorization of its COVID-19 vaccine in kids under age 6.
Zenger · Apr 28, 2022 World’s First AI-Ready Infrasound Stethoscope Gets FDA Approval Sanolla’s VoqX can hear infrasound acoustic waves which, when analyzed by AI algorithms, supply lifesaving diagnostic insights.
Benzinga · Apr 27, 2022 SQZ Biotechnologies Receives FDA Fast Track Designation for SQZ-PBMC-HPV for the Treatment of HPV16+ Tumors SQZ Biotechnologies (NYSE: SQZ) received Fast Track Designation from he U.S. Food and Drug Administration (FDA) for its lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors. SQZ-PBMC-HPV-101 is currently being investigated in the Phase 1/2 clinical study.
The Guardian - US · Apr 27, 2022 McKinsey denies illegally hiding work for opioid-maker Purdue Pharma while advising FDA Consulting firm was protecting client confidentiality, chief says, and wasn’t obliged to disclose work advising drug manufacturer
Benzinga · Apr 27, 2022 Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…
Benzinga · Apr 27, 2022 Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients Gamida Cell Ltd (NASDAQ:GMDA) announced that updated infection data on omidubicel compared to umbilical cord blood transplantation (UCB) was shared at the Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings. The data from a sub-study of the Phase 3 trial of omidubicel showed early and enhanced recovery of various immune cells, including…
The Independent UK · Apr 27, 2022 McKinsey exec faces questions on opioid, FDA consulting work A top McKinsey executive is answering congressional questions about his company’s consulting work for the Food and Drug Administration even as it advised opioid drugmakers on boosting sales
Benzinga · Apr 27, 2022 Why Molecular Partners Shares Are Getting Hammered Molecular Partners AG (NASDAQ: MOLN) shares are trading lower by 36.52% at $8.38 after the company and its partner Novartis expects the FDA may require additional clinical data for the Emergency Use Application for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19.
Benzinga · Apr 27, 2022 Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…
Benzinga · Apr 27, 2022 Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…